Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Strains: Influence of Bacterial Inoculum

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Jul 27

PMID 39061345

Authors

Celia Garcia-Rivera

Antonia Sanchez-Bautista

Monica Parra-Grande

Andrea Ricart-Silvestre

Maria Paz Ventero

Iryna Tyshkovska

Esperanza Merino

Juan Carlos Rodriguez Diaz

Affiliations

Soon will be listed here.

Abstract

Carbapenem-resistant infections represent a critical public health concern, highlighting the need for the development of effective antibiotics. Cefiderocol demonstrated potent in vitro activity against , particularly in strains that are resistant to other drugs. However, concerns regarding the emergence of drug-resistant strains persist. This study, conducted with 109 carbapenem-resistant strains from the Spanish Hospital (Dr. Balmis, Alicante). The study evaluated susceptibility to cefiderocol in comparison to alternative antibiotics and including their susceptibility to bacterial inoculum, while assessing various testing methods. Our findings revealed high susceptibility to cefiderocol against carbapenem-resistant strains, with only 2 of 109 strains exhibiting resistance. Comparative analysis demonstrated superiority of cefiderocol towards alternative antibiotics. Both the E-test and disk-diffusion methods showed 100% concordance with the microdilution method in classifying strains as susceptible or resistant. However, 4.6% (5/109) of disc zone diameters fell within the technical uncertainty zone, so the E-test technique was found to be more useful in routine clinical practice. Additionally, escalating bacterial inoculum correlated with decreases in vitro activity, so this parameter should be adjusted very carefully in in vivo studies. This study underscores cefiderocol's potential as a therapeutic option for carbapenem-resistant infections. However, the emergence of drug-resistant strains emphasizes the critical need for a wise use of antibiotics and a continuous monitoring of resistance to antibiotics. Based on our in vitro data, further investigation concerning the impact of bacterial inoculum on drug efficacy is warranted in order to detect resistance mechanisms and optimize treatment strategies, thereby mitigating the risk of resistance.

References

Liu H, Yang L, Chen Q, Song H, Bo X, Guo J . Time Series Genomics of Pseudomonas aeruginosa Reveals the Emergence of a Hypermutator Phenotype and Within-Host Evolution in Clinical Inpatients. Microbiol Spectr. 2022; 10(4):e0005722. PMC: 9430856. DOI: 10.1128/spectrum.00057-22. View

Raro O, Bouvier M, Kerbol A, Poirel L, Nordmann P . MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. Int J Antimicrob Agents. 2024; 64(2):107206. DOI: 10.1016/j.ijantimicag.2024.107206. View

Jean S, Gould I, Lee W, Hsueh P . New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs. 2019; 79(7):705-714. DOI: 10.1007/s40265-019-01112-1. View

Laffont-Lozes P, Larcher R, Salipante F, Leguelinel-Blache G, Dunyach-Remy C, Lavigne J . Usefulness of dynamic regression time series models for studying the relationship between antimicrobial consumption and bacterial antimicrobial resistance in hospitals: a systematic review. Antimicrob Resist Infect Control. 2023; 12(1):100. PMC: 10496333. DOI: 10.1186/s13756-023-01302-3. View

Wicky P, Poiraud J, Alves M, Patrier J, dHumieres C, Le M . Cefiderocol Treatment for Severe Infections due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review. Antibiotics (Basel). 2023; 12(6). PMC: 10295316. DOI: 10.3390/antibiotics12060991. View

Vuillemin X, Da Silva M, Bour M, Landon C, Plesiat P, Jeannot K . Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa. Int J Antimicrob Agents. 2023; 62(3):106917. DOI: 10.1016/j.ijantimicag.2023.106917. View

Dortet L, Niccolai C, Pfennigwerth N, Frisch S, Gonzalez C, Antonelli A . Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria. J Antimicrob Chemother. 2023; 78(7):1672-1676. PMC: 10320108. DOI: 10.1093/jac/dkad149. View

Bianco G, Boattini M, Comini S, Banche G, Cavallo R, Costa C . Disc Diffusion and ComASP Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine. Antibiotics (Basel). 2023; 12(3). PMC: 10045311. DOI: 10.3390/antibiotics12030604. View

Wang C, Yang D, Wang Y, Ni W . Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence. Front Pharmacol. 2022; 13:896971. PMC: 9039133. DOI: 10.3389/fphar.2022.896971. View

10.

Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis E . Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect. 2023; 30(2):178-188. DOI: 10.1016/j.cmi.2023.08.029. View

11.

Lanckohr C, Bracht H . Antimicrobial stewardship. Curr Opin Crit Care. 2022; 28(5):551-556. DOI: 10.1097/MCC.0000000000000967. View

12.

Karruli A, Catalini C, DAmore C, Foglia F, Mari F, Harxhi A . Evidence-Based Treatment of Infections: A Critical Reappraisal. Antibiotics (Basel). 2023; 12(2). PMC: 9952410. DOI: 10.3390/antibiotics12020399. View

13.

Witzany C, Regoes R, Igler C . Assessing the relative importance of bacterial resistance, persistence and hyper-mutation for antibiotic treatment failure. Proc Biol Sci. 2022; 289(1986):20221300. PMC: 9653239. DOI: 10.1098/rspb.2022.1300. View

14.

Domingues S, Lima T, Saavedra M, da Silva G . An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms. Life (Basel). 2023; 13(7). PMC: 10382032. DOI: 10.3390/life13071427. View

15.

Bianco G, Gaibani P, Comini S, Boattini M, Banche G, Costa C . Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms. Antibiotics (Basel). 2022; 11(12). PMC: 9774952. DOI: 10.3390/antibiotics11121681. View

16.

Brakert L, Berneking L, Both A, Berinson B, Huang J, Aepfelbacher M . Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway. J Glob Antimicrob Resist. 2023; 34:59-62. DOI: 10.1016/j.jgar.2023.06.003. View

17.

Avakh A, Grant G, Cheesman M, Kalkundri T, Hall S . The Art of War with : Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy. Antibiotics (Basel). 2023; 12(8). PMC: 10451789. DOI: 10.3390/antibiotics12081304. View

18.

Marcos Fendian A, Albanell-Fernandez M, Tuset M, Pitart C, Castro P, Soy D . Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series. Infect Dis Ther. 2023; 12(4):1205-1216. PMC: 10029777. DOI: 10.1007/s40121-023-00776-3. View

19.

Kalpana S, Lin W, Wang Y, Fu Y, Lakshmi A, Wang H . Antibiotic Resistance Diagnosis in ESKAPE Pathogens-A Review on Proteomic Perspective. Diagnostics (Basel). 2023; 13(6). PMC: 10047325. DOI: 10.3390/diagnostics13061014. View

20.

Karakonstantis S, Rousaki M, Kritsotakis E . Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics (Basel). 2022; 11(6). PMC: 9220290. DOI: 10.3390/antibiotics11060723. View